Advanced

Treatment with belimumab in systemic lupus erythematosus does not impair antibody response to 13-valent pneumococcal conjugate vaccine.

Nagel, Johanna LU ; Geborek, Pierre LU ; Bengtsson, Anders LU ; Jacobsen, S; Joergensen C, Svaerke ; Nilsson, Jan-Åke LU ; Skattum, Lillemor Melander LU ; Jönsen, Andreas LU and C Kapetanovic, Meliha LU (2017) In Lupus 1. p.1-10
Abstract
Background/purpose: The objective of this study was to explore the impact of systemic lupus
erythematosus and belimumab given in addition to standard of care therapy on 13-valent
conjugated pneumococcal vaccine (PCV13) response. Methods: Forty-seven systemic lupus
erythematosus patients and 21 healthy controls were immunized with a single dose of
13-valent conjugated pneumococcal vaccine. Forty systemic lupus erythematosus patients
were treated with traditional disease-modifying anti rheumatic drugs, 11 of those received
belimumab in addition, and 32 patients were treated with concomitant prednisolone.
Quantification of serotype specific IgG levels to 12 pneumococcal capsular polysaccharides
was performed in... (More)
Background/purpose: The objective of this study was to explore the impact of systemic lupus
erythematosus and belimumab given in addition to standard of care therapy on 13-valent
conjugated pneumococcal vaccine (PCV13) response. Methods: Forty-seven systemic lupus
erythematosus patients and 21 healthy controls were immunized with a single dose of
13-valent conjugated pneumococcal vaccine. Forty systemic lupus erythematosus patients
were treated with traditional disease-modifying anti rheumatic drugs, 11 of those received
belimumab in addition, and 32 patients were treated with concomitant prednisolone.
Quantification of serotype specific IgG levels to 12 pneumococcal capsular polysaccharides
was performed in serum taken before and four to six weeks after vaccination using multiplex
fluorescent microsphere immunoassay. IgG levels against serotypes 23F and 6B were also
analyzed using standard enzyme-linked immunosorbent assays. Opsonophagocytic
assay was performed on serotype 23F to evaluate the functionality of the antibodies. Preand
post-vaccination log transformed antibody levels were compared to determine the
impact of systemic lupus erythematosus diagnosis and different treatments on antibody
response. Results: Systemic lupus erythematosus patients as a group showed lower postvaccination
antibody levels and lower fold increase of antibody levels after vaccination
compared to controls (p¼0.02 and p¼0.009, respectively). Systemic lupus erythematosus
patients treated with belimumab in addition to standard of care therapy or with only hydroxychloroquine
did not differ compared to controls, whereas the other treatment groups had
significantly lower fold increase of post-vaccination antibody levels. Higher age was associated
with lower post-vaccination antibody levels among systemic lupus erythematosus
patients. Conclusion: Belimumab given in addition to traditional disease-modifying
anti rheumatic drugs or prednisolone did not further impair antibody response to 13-valent
conjugated pneumococcal vaccine. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
belimumab , systemic lupus
in
Lupus
volume
1
pages
10 pages
publisher
SAGE Publications
external identifiers
  • pmid:28420056
  • scopus:85027554888
ISSN
0961-2033
language
English
LU publication?
yes
id
288448f3-2d1e-445e-b33e-785410d60f76
alternative location
http://journals.sagepub.com/doi/abs/10.1177/0961203317695465?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed
date added to LUP
2017-06-19 09:55:54
date last changed
2017-09-03 05:23:41
@article{288448f3-2d1e-445e-b33e-785410d60f76,
  abstract     = {Background/purpose: The objective of this study was to explore the impact of systemic lupus<br/>erythematosus and belimumab given in addition to standard of care therapy on 13-valent<br/>conjugated pneumococcal vaccine (PCV13) response. Methods: Forty-seven systemic lupus<br/>erythematosus patients and 21 healthy controls were immunized with a single dose of<br/>13-valent conjugated pneumococcal vaccine. Forty systemic lupus erythematosus patients<br/>were treated with traditional disease-modifying anti rheumatic drugs, 11 of those received<br/>belimumab in addition, and 32 patients were treated with concomitant prednisolone.<br/>Quantification of serotype specific IgG levels to 12 pneumococcal capsular polysaccharides<br/>was performed in serum taken before and four to six weeks after vaccination using multiplex<br/>fluorescent microsphere immunoassay. IgG levels against serotypes 23F and 6B were also<br/>analyzed using standard enzyme-linked immunosorbent assays. Opsonophagocytic<br/>assay was performed on serotype 23F to evaluate the functionality of the antibodies. Preand<br/>post-vaccination log transformed antibody levels were compared to determine the<br/>impact of systemic lupus erythematosus diagnosis and different treatments on antibody<br/>response. Results: Systemic lupus erythematosus patients as a group showed lower postvaccination<br/>antibody levels and lower fold increase of antibody levels after vaccination<br/>compared to controls (p¼0.02 and p¼0.009, respectively). Systemic lupus erythematosus<br/>patients treated with belimumab in addition to standard of care therapy or with only hydroxychloroquine<br/>did not differ compared to controls, whereas the other treatment groups had<br/>significantly lower fold increase of post-vaccination antibody levels. Higher age was associated<br/>with lower post-vaccination antibody levels among systemic lupus erythematosus<br/>patients. Conclusion: Belimumab given in addition to traditional disease-modifying<br/>anti rheumatic drugs or prednisolone did not further impair antibody response to 13-valent<br/>conjugated pneumococcal vaccine.},
  author       = {Nagel, Johanna and Geborek, Pierre and Bengtsson, Anders and Jacobsen, S and Joergensen C, Svaerke  and Nilsson, Jan-Åke and Skattum, Lillemor Melander and Jönsen, Andreas and C Kapetanovic, Meliha},
  issn         = {0961-2033},
  keyword      = { belimumab ,systemic lupus},
  language     = {eng},
  month        = {01},
  pages        = {1--10},
  publisher    = {SAGE Publications},
  series       = {Lupus},
  title        = {Treatment with belimumab in systemic lupus erythematosus does not impair antibody response to 13-valent pneumococcal conjugate vaccine.},
  volume       = {1},
  year         = {2017},
}